Adaptive NK Cell Platform Shows Safety for Hematological Malignancies
June 11th 2022Jeffrey S. Miller, MD, discusses the findings of a study of the Tri-Specific Killer Engager platform for the activation of natural killer cells for the treatment of refractory acute myeloid leukemia and other cancers.